InSilico Medicine Cayman TopCo (ISLMF)

Market Cap	3.50B
Revenue (ttm)	56.24M -34.5%
Net Income	-352.32M
EPS	-4.48
Shares Out	n/a
PE Ratio	n/a
Forward PE	156.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	5.59
Previous Close	5.50
Day's Range	5.59 - 6.35
52-Week Range	4.20 - 9.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About ISLMF

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, softwar...

• Industry: Prepackaged Software
• Founded: 2014
• Employees: 317
• Stock Exchange: OTCMKTS
• Ticker Symbol: ISLMF

Financial Performance

In 2025, ISLMF's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 11, 2026

Data Sources Report a data error